Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05713760 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults
A Phase 2 study of Superficial Basal Cell Carcinoma, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05713760 is a Phase 2 study of Superficial Basal Cell Carcinoma that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 5 participants, below the 115-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05713760, a Phase 2 study of Superficial Basal Cell Carcinoma, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).
Conditions Studied
Interventions
- DRUG Tirbanibulin Ointment 1%
Study Locations (1)
Texas
- Austin Institute for Clinical Research, Inc. - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05713760
The ClinicalTrials.gov registry entry for NCT05713760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (96% lower). The listed sponsor is Austin Institute for Clinical Research, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Superficial Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Tirbanibulin Ointment 1% is the first listed.
NCT05713760 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05713760 about?
NCT05713760 is a clinical study titled "Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults". This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).
What is the current status of trial NCT05713760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-04-17. Estimated completion is 2024-03-07.
What conditions does trial NCT05713760 study?
This clinical trial studies the following conditions: Superficial Basal Cell Carcinoma.
What interventions are being tested in trial NCT05713760?
The interventions under investigation include: Tirbanibulin Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT05713760?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05713760 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Superficial Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
RECRUITING · Phase 2
-
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
RECRUITING · Phase 1
-
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
RECRUITING · NA
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.